Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research note published on Friday, Benzinga reports. The brokerage currently has a $107.00 price target on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an overweight rating in a research note on Monday, March 18th. Robert W. Baird boosted their price target on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an outperform rating in a research note on Tuesday, January 30th. Wedbush dropped their target price on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a neutral rating on the stock in a research report on Friday. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a buy rating in a report on Wednesday, February 21st. Finally, TD Cowen boosted their price target on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a buy rating in a report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $88.00.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded down $0.38 during trading on Friday, reaching $42.37. 48,782 shares of the company traded hands, compared to its average volume of 759,648. The firm has a 50 day simple moving average of $47.25 and a 200-day simple moving average of $44.22. Ultragenyx Pharmaceutical has a 52-week low of $31.52 and a 52-week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative return on equity of 421.88% and a negative net margin of 138.58%. The firm had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. During the same quarter in the previous year, the business posted ($2.33) EPS. Ultragenyx Pharmaceutical’s revenue was up 8.3% on a year-over-year basis. As a group, analysts anticipate that Ultragenyx Pharmaceutical will post -6.38 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now directly owns 89,268 shares in the company, valued at approximately $4,799,047.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the transaction, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider John Richard Pinion sold 4,173 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the transaction, the insider now owns 89,268 shares in the company, valued at $4,799,047.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,116 shares of company stock worth $1,645,983. 6.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its position in Ultragenyx Pharmaceutical by 390.4% during the 3rd quarter. SG Americas Securities LLC now owns 12,156 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 9,677 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 127.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 22,108 shares of the biopharmaceutical company’s stock worth $788,000 after acquiring an additional 12,403 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Ultragenyx Pharmaceutical by 19.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,136 shares of the biopharmaceutical company’s stock worth $504,000 after acquiring an additional 2,292 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Ultragenyx Pharmaceutical by 9.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 210,968 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 18,845 shares during the last quarter. Finally, TD Asset Management Inc lifted its stake in Ultragenyx Pharmaceutical by 74.4% in the 3rd quarter. TD Asset Management Inc now owns 205,360 shares of the biopharmaceutical company’s stock valued at $7,321,000 after purchasing an additional 87,580 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.